HUTCHMED (China) Limited
HUTCHMED (China) Limited (HCM.L) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for HUTCHMED (China) Limited (HCM.L), covering cash flow, earnings, and balance sheets.
HUTCHMED (China) Limited (HCM.L) Income Statement & Financial Overview
Explore comprehensive income reports for HUTCHMED (China) Limited HCM.L, broken down by year and quarter.
| Metric | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $152.84M | $152.84M | $152.56M | $152.56M |
| Cost of Revenue | $90.07M | $90.07M | $166.75M | $166.75M |
| Gross Profit | $62.77M | $62.77M | -$14.18M | -$14.18M |
| Gross Profit Ratio | $0.41 | $0.41 | -$0.09 | -$0.09 |
| R&D Expenses | $47.63M | $47.63M | $79.21M | $79.21M |
| SG&A Expenses | $28.91M | $28.91M | $32.46M | $32.46M |
| Operating Expenses | $76.53M | $76.53M | $36.92M | $36.92M |
| Total Costs & Expenses | $166.60M | $166.60M | $203.66M | $203.66M |
| Interest Income | $0.00 | $0.00 | $17.80M | $17.80M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $3.13M | $3.13M | $2.20M | $2.20M |
| EBITDA | -$10.63M | -$10.63M | -$44.44M | -$44.44M |
| EBITDA Ratio | -$0.07 | -$0.07 | -$0.29 | -$0.29 |
| Operating Income | -$13.76M | -$13.76M | -$46.64M | -$46.64M |
| Operating Income Ratio | -$0.09 | -$0.09 | -$0.31 | -$0.31 |
| Other Income/Expenses (Net) | $28.29M | $28.29M | $13.34M | $13.34M |
| Income Before Tax | $14.53M | $14.53M | -$33.30M | -$33.30M |
| Income Before Tax Ratio | $0.10 | $0.10 | -$0.22 | -$0.22 |
| Income Tax Expense | $1.44M | $1.44M | $889500.00 | $889500.00 |
| Net Income | $12.90M | $12.90M | -$33.89M | -$33.89M |
| Net Income Ratio | $0.08 | $0.08 | -$0.22 | -$0.22 |
| EPS | $0.01 | $0.01 | -$0.04 | -$0.04 |
| Diluted EPS | $0.01 | $0.01 | -$0.04 | -$0.04 |
| Weighted Avg Shares Outstanding | $860.03M | $860.03M | $852.40M | $852.40M |
| Weighted Avg Shares Outstanding (Diluted) | $872.53M | $872.53M | $852.38M | $852.38M |
Over the last four quarters, HUTCHMED (China) Limited's revenue moved from $152.56M in Q3 2023 to $152.84M in Q2 2024. Operating income in Q2 2024 was -$13.76M, with a strong operating margin of -9%. Despite fluctuations in R&D and SG&A expenses, EBITDA for HUTCHMED (China) Limited remained robust at -$10.63M, reflecting operational efficiency. Net income rose to $12.90M, with an EPS of $0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan